Literature DB >> 30843894

Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.

Constantine S Tam1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30843894

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  2 in total

1.  Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.

Authors:  Todd Covey; Sarah E M Herman; Adrian Wiestner; Anfal Alsadhan; Jean Cheung; Michael Gulrajani; Erika M Gaglione; Pia Nierman; Ahmed Hamdy; Raquel Izumi; Elena Bibikova; Priti Patel; Clare Sun
Journal:  Clin Cancer Res       Date:  2020-02-13       Impact factor: 12.531

Review 2.  COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.

Authors:  Anup S Pathania; Philip Prathipati; Bakrudeen Aa Abdul; Srinivas Chava; Santharam S Katta; Subash C Gupta; Pandu R Gangula; Manoj K Pandey; Donald L Durden; Siddappa N Byrareddy; Kishore B Challagundla
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.